Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
2+ (equivocal) to the original FDA-approved criteria. Repeat HER2 testing on a surgical specimen if the initially tested core biopsy is negative is no longer stated as mandatory. A new HER2 test may (no longer should ) be ordered on the excision specimen on the basis of some criteria (such as tumor grade 3). A more rigorous interpretation criteria of the less common patterns that can be seen in about 5% of all cases when HER2 status in breastcancer is evaluated using a dual-probe ISH testing (...) HER2 Testing in BreastCancer - 2018 Focused Update HER2 Testing in BreastCancer -… | College of American Pathologists Group CAP_logo_rgb User Toggle Navigation Menu Search Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow HER2 Testing in BreastCancer - 2018 Focused Update HER2 Testing in BreastCancer - 2018 Focused Update To address new information made available since the 2013 “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in BreastCancer
Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breastcancer Neoadjuvant chemotherapy for breastcancer has the potential to achieve a pathological complete response in up to 40 per cent of patients, converting disease that was initially node-positive to node-negative. This has raised the question of whether sentinel lymph node biopsy could be an alternative to axillary lymph node dissection in these patients (...) . The aim was to undertake a systematic review and meta-analysis of the accuracy and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer.A literature search was conducted using PubMed, Ovid MEDLINE, Embase and Web of Science databases up to 30 April 2017. Inclusion criteria for studies were pathological confirmation of initial node-positive disease, and sentinel lymph node biopsy performed after neoadjuvant
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive BreastCancer: A Systematic Review and Meta-analysis The aim of this study was to perform a systematic review and meta-analysis to assess the accuracy of different surgical axillary staging procedures compared with ALND.Optimal axillary staging after neoadjuvant systemic therapy (NST) in node-positive breastcancer is an area of controversy. Several less invasive (...) confirmed node-positive breastcancer (cN+). A meta-analysis was performed to compare identification rate (IFR), false-negative rate (FNR), and negative predictive value (NPV).Of 1132 records, 20 unique studies with 2217 patients were included in quantitative analysis: 17 studies on SLNB, 1 study on MARI, and 2 studies on a combination procedure. Overall axillary pathologic complete response rate was 37%. For SLNB, pooled rates of IFR and FNR were 89% and 17%. NPV ranged from 57% to 86%. For MARI, IFR
paclitaxel. The primary efficacy outcome was the pCR rate, absence of invasive tumour in breast and nodal tissue and absence of ductal carcinoma in situ; in the subgroup with HER2-positive cancer, the pCR rates were 62% (123/199) of patients given nab-paclitaxel, and 54% (106/197) of patients given paclitaxel. The tpCR rate was a secondary outcome but was not reported for the subgroup with HER2 cancer. 6 Summary of evidence on comparative safety In the NeoSphere study, most adverse events were grade 1/2 (...) equivalent medicine, in the context of treatments currently available in NHS Scotland. The key points expressed by the group were: • HER-2 positive breasttumours are associated with higher rates of recurrence and an increased mortality compared to other breastcancers. • Patients are prepared to undergo disfiguring surgery and treatment with associated significant toxicity in an attempt to cure their disease. Surgery for early breastcancer can cause scarring and be very traumatic for patients
Herceptin® (trastuzumab) in HER2-positive early breastcancer: a systematic review and cumulative network meta-analysis. Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breastcancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy for HER2+ EBC patients and how the OS advantage changed over time.A systematic literature review
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breastcancer The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX BreastCancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breastcancer when recurrence score (RS) was ≥31. HER2 is a component of the RS algorithm with a positive coefficient and contributes to higher RS values. Accrual to B-20 occurred prior to routine
mTORC1 is a key mediator of RON-dependent breastcancer metastasis with therapeutic potential Metastasis is the biggest challenge in treating breastcancer, and it kills >40,000 breastcancer patients annually in the US. Aberrant expression of the RON receptor tyrosine kinase in breasttumors correlates with poor prognosis and has been shown to promote metastasis. However, the molecular mechanisms that govern how RON promotes metastasis, and how to block it, are still largely unknown. We sought (...) to determine critical effectors of RON using a combination of mutational and pharmacologic strategies. High-throughput proteomic analysis of breastcancer cells upon activation of RON showed robust phosphorylation of ribosomal protein S6. Further analysis revealed that RON strongly signals through mTORC1/p70S6K, which is mediated predominantly by the PI3K pathway. A targeted mutation approach to modulate RON signaling validated the importance of PI3K/mTORC1 pathway for spontaneous metastasis in vivo
iSunyer), Hospital Cli ´nic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain; 35 Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; 36 Oncology Division, Stanford University Medical Center, Stanford, USA; 37 Policy Department, BreastCancer Network Australia, Camberwell, VIC, Australia; 38 Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany; 39 Oncology (...) : firstname.lastname@example.org † These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO). Keywords: breastcancer, metastatic, advanced, guidelines, ABC, ESO-ESMO Advanced BreastCancer (ABC) comprises both locally advanced breastcancer (LABC) and metastatic breastcancer (MBC) . Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of3 years and a 5-year sur- vival of only25% [2, 3
the company, because of the G-BA’s specification of the ACT, could choose a comparator therapy from several options, the respective choice of the company is printed in bold. b: The relevant study compared ribociclib + letrozole with placebo + letrozole. Patients with stage IV disease (breastcancer with distant metastasis) and an ECOG PS of 0 or 1 were included. It remains unclear whether the observed effects can be transferred to patients with ECOG PS = 2 or with other disease stages. ACT: appropriate (...) Ribociclib (breastcancer) ? Addendum to Commission A17-45 1 Translation of addendum A18-07 Ribociclib (Mammakarzinom) – Addendum zum Auftrag A17-45 (Version 1.0; Status: 7 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 7 February 2018 1.0 Commission: A18-07 Version: Status: IQWiG Reports – Commission No. A18-07 Ribociclib (breast
35685-1 E-mail: email@example.com Internet: www.iqwig.de Executive summary of addendum D18-01 Version 1.1 Biomarkers in breastcancer 5 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - This addendum was prepared without the collaboration of external experts. IQWiG employees involved in the addendum: ? Martina Markes ? Lars Beckmann ? Daniel Fleer ? Wiebke Sieben Keywords: tumor markers – biological, breastneoplasms, benefit assessment Executive summary of addendum (...) ) was shown for the randomized group of patients with an RS of 11 to 25 for the outcome “disease-free survival”. However, no non-inferiority of endocrine therapy for these patients can be derived from the results as it cannot be excluded that the risk difference after 9 years is more Executive summary of addendum D18-01 Version 1.1 Biomarkers in breastcancer 5 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - than the threshold of 3 percentage points used
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced BreastCancer (PERTAIN): A Randomized, Open-Label Phase II Tr To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breastcancer (MBC/LABC).The PERTAIN
Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of BreastCancer Treatment To evaluate clinical outcomes of using acellular dermal matrix (ADM) with implant based breast reconstructions (IBBRs) in a randomized controlled trial.The use of ADMs in IBBRs is widespread, but link between ADM and complications remain a controversial topic. In view of reports concerning harm, we present 6-months (...) safety data of ADM-assisted IBBR in the setting of breastcancer treatment.An open-label, randomized, controlled trial recruiting patients from 4 centers in Sweden and 1 in UK. Eligible were women with breastcancer planned for mastectomy with immediate IBBR. Participants were randomly allocated to IBBR with or without ADM (Strattice, Branchburg, NJ), with stratification by center in blocks of 6. Main primary endpoint was number of unplanned reoperations at 24 months, and safety expressed
Axillary dissection versus no axillary dissection in patients with breastcancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breastcancer with one or more micrometastatic (≤2 mm) sentinel nodes randomly assigned to either axillary dissection or no axillary dissection. The results showed no difference (...) diagnosis of breastcancer with largest lesion diameter of 5 cm or smaller, and one or more metastatic sentinel nodes, all of which were 2 mm or smaller and with no extracapsular extension. Patients were randomly assigned (1:1) before surgery (mastectomy or breast-conserving surgery) to no axillary dissection or axillary dissection using permuted blocks generated by a web-based congruence algorithm, with stratification by centre and menopausal status. The protocol-specified primary endpoint was disease
cancer cells. What benefits of Verzenios have been shown in studies? Two main studies, involving 1,162 women, mostly postmenopausal, with HR-positive, HER2-negative breastcancer that had started to spread, showed that Verzenios can prolong the time patients live without their disease getting worse (progression-free survival). In the first study women taking Verzenios and an aromatase inhibitor (letrozole or anastrozole) lived on average 28 months without their disease getting worse compared with 15 (...) months for women taking placebo (a dummy treatment) and an aromatase inhibitor. In the second study women taking Verzenios and fulvestrant lived on average 16 months without their disease getting worse, compared with 9 months for women taking placebo and fulvestrant. A third study, conducted in 132 women who had received previous cancer treatment, failed to demonstrate that Verzenios used on its own was of benefit in the treatment of HR-positive, HER2- negative breastcancer that had started
Talazoparib (Talzenna) - For the treatment of locally advanced or metastatic breastcancer patients with a germline BRCA mutation Drug Approval Package: Talzenna (talazoparib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Talzenna (talazoparib) Company: Pfizer, Inc Application Number: 211651 Approval Date: 10/16/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter
An assessment of prognostic immunity markers in breastcancerTumor-infiltrating lymphocytes (TIL) and immunity gene signatures have been reported to be significantly prognostic in breastcancer but have not yet been applied for calculation of risk of recurrence in clinical assays. A compact set of 17 immunity genes was derived herein from an Affymetrix-derived gene expression dataset including 1951 patients (AFFY1951). The 17 immunity genes demonstrated significant prognostic stratification (...) of estrogen receptor (ER)-negative breastcancer patients with high proliferation gene expression. Further analysis of blood and breastcancer single-cell RNA-seq datasets revealed that the 17 immunity genes were derived from TIL that were inactive in the blood and became active in tumor tissue. Expression of the 17 immunity genes was significantly (p < 2.2E-16, n = 91) correlated with TILs percentage on H&E in triple negative breastcancer. To demonstrate the impact of tumor immunity genes on prognosis
Risk factors for the development of brain metastases in patients with HER2-positive breastcancer Patients with metastatic human epidermal growth factor receptor 2-positive breastcancer (HER2+ BC) frequently experience brain metastases (BM). We aimed to define risk factors for the development of BM in patients with HER2+ BC and to report on their outcome.This is a retrospective analysis of patients diagnosed with HER2+ BC between January 2000 and December 2014 at Institut Jules Bordet, Belgium (...) . Statistical analyses were conducted with SAS V.9.4 using Kaplan-Meier method and Cox regression analyses.A total of 483 patients were included of whom 108 (22.4%) developed metastases and 52 (10.8%) BM. Among 96 metastatic patients without BM at diagnosis, 40 (41.7%) developed BM in the course of their disease. In multivariate analysis, risk factors for the development of BM were age ≤40 years (HR 2.10, 95 % CI 1.02 to 4.36), tumour size >2 cm (HR 4.94, 95% CI 1.69 to 14.47), nodal involvement (HR 3.48
advanced breastcancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus fulvestrant or placebo plus fulvestrant. We analyzed overall survival; the effect of palbociclib according to the prespecified stratification factors of presence or absence of sensitivity to endocrine therapy, presence or absence of visceral metastatic disease, and menopausal status; the efficacy of subsequent therapies after disease progression; and safety.Among 521 patients who (...) Overall Survival with Palbociclib and Fulvestrant in Advanced BreastCancer. The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer. We report the results of a prespecified analysis of overall survival.We randomly assigned patients with hormone-receptor-positive, HER2-negative